



OPEN ACCESS

APPROVED BY

Michael Heinrich,
University College London, United Kingdom

*CORRESPONDENCE

Frontiers Editorial Office,
✉ research.integrity@frontiersin.org

RECEIVED 18 November 2024

ACCEPTED 25 November 2024

PUBLISHED 02 December 2024

CITATION

Frontiers Editorial Office (2024) Retraction:
Corrigendum: ErHuang formula improves renal
fibrosis in diabetic nephropathy rats by
inhibiting CXCL6/JAK/STAT3 signaling pathway.
Front. Pharmacol. 15:1530384.
doi: 10.3389/fphar.2024.1530384

COPYRIGHT

© 2024 Frontiers Editorial Office. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or reproduction in
other forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Retraction: Corrigendum: ErHuang formula improves renal fibrosis in diabetic nephropathy rats by inhibiting CXCL6/JAK/ STAT3 signaling pathway

Frontiers Editorial Office*

A Retraction of the Correction article

Corrigendum: ErHuang formula improves renal fibrosis in diabetic nephropathy rats by inhibiting CXCL6/JAK/STAT3 signaling pathway

by Shen Y-L, Jiang Y-p, Li X-Q, Wang S-J, Ma M-H, Zhang C-Y, Zhu J-Y, Rahman K, Zhang L-J, Luan X and Zhang H (2021). *Front. Pharmacol.* 12:789192. doi: 10.3389/fphar.2021.789192

The journal retracts the 18 November 2021 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures in the published article. Image duplication concerns were identified in Figures 4E and 5C. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agreed to this retraction.